HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates.
JHEP Rep
; 4(12): 100580, 2022 Dec.
Article
in En
| MEDLINE
| ID: mdl-36316992
Antiviral therapy; BP, bodily pain; DAA, direct-acting antivirals; DBS, dried blood spot; DDIs, drugdrug interactions; Dried blood spot testing; Drug users; FU12, 12 weeks of follow-up; GH, general health; HRC, harm reduction centre; Hepatitis C; High-risk practices; LSM, liver stiffness measurement; MCS, mental component summary; MH, mental health; NSPs, needle and syringe programmes; OR, odds ratio; OST, opioid substitution therapy; PCS, physical component summary; PF, physical functioning; PP, per protocol; PWID, people who inject drugs; PoCT, point-of-care testing; RE, role emotional; RP, role physical; SF, social functioning; SVR, sustained virologic response; SVR12, sustained virologic response at 12 weeks; TARGA, antiretroviral therapy; VT, vitality
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Risk_factors_studies
Aspects:
Patient_preference
Language:
En
Journal:
JHEP Rep
Year:
2022
Document type:
Article
Affiliation country:
España
Country of publication:
Países Bajos